Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03555019
Other study ID # 2016-003700-31
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 13, 2018
Est. completion date May 30, 2029

Study information

Verified date September 2021
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this double-blind randomized study is to assess the effects of an early, enhanced supply of the essential fatty acids (FAs) arachidonic acid (ARA) and docosahexaenoic acid (DHA) on brain maturation, clinical outcomes and quality of growth in immature infants (gestational age <29 weeks) as compared to standard nutrient supply.


Description:

This is a double-blind randomized study. 172 preterm infants with gestational age < 29 weeks will be enrolled. The intervention group will receive enteral supplementation with essential fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA). The control group will receive standard supplementation with medium-chain triglycerides (MCT-oil). The main hypothesis is that early, enhanced supply of ARA and DHA will improve brain growth and maturation, as compared to standard nutrient supply. Secondary hypotheses are that early, enhanced supply of ARA and DHA will improve quality of growth and cognitive development as well as reduce the frequency of inflammation-related neonatal comorbidities and long-term cardiovascular disease risk. Primary endpoint will be assessed by magnetic resonance imaging (MRI) of the brain at term equivalent age.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 121
Est. completion date May 30, 2029
Est. primary completion date May 28, 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 48 Hours
Eligibility Inclusion Criteria: - Extremely preterm infants born at Oslo University Hospital (OUH) - Gestational age (GA) < 29 weeks - Less than 48 hours of age at inclusion - Signed informed consent and expected Cooperation of the patients for the treatment and follow up must be obtained and documented according to good clinical practice (GCP) and national/local regulations Exclusion Criteria: - Major congenital malformations which will affect growth and development - Chromosomal abnormalities and other genetic diseases - Critical illness with short life expectancy as defined by the study physician

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Formulaid
Supplementation with ARA and DHA
MCT-oil
Supplementation with medium chain fatty acids

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (4)

Lead Sponsor Collaborator
Oslo University Hospital Umeå University, University of Geneva, Switzerland, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain maturation assessed by magnetic resonance imaging (MRI) MRI with spectroscopy (MRS) and diffusion tensor imaging (DTI) will be used to examine myelinisation and quantification of anatomical structures as well as neuronal integrity and inflammation 40 weeks postmenstrual age (PMA)
Secondary Weight gain Weight measurements, including weight nadir. Weight will be recorded until 36 weeks PMA and at 3, 6, 12 and 24 months and 8 years corrected age.
Secondary Growth Length and head circumference (HC). Length and HC will be recorded until 36 weeks PMA and at 3, 6, 12 and 24 months and 8 years corrected age.
Secondary Body composition Body composition will be assessed using PEA POD, an air displacement plethysmography system and Dexa Scan. At 36 weeks PMA, 3 months and 2 years corrected age
Secondary Neonatal morbidities associated with inflammation Bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), white matter injury (WMI) of the brain, and late onset septicemia From birth til 36 weeks PMA
Secondary Cerebral Background Activity evaluated by Electroencephalogram (EEG) EEG maturational changes will be examined as a function of time and as a function of gestational age First week of life, 36 weeks PMA and 2 years corrected age (CA)
Secondary Neurodevelopment assessed by standardized motor and cognitive tests Evaluation of psychomotor development by performing Bayley III and a standardized neurological examination 2 years corrected age (CA)
Secondary Lung function evaluated by tidal breathing measurements Tidal breathing measurements include tidal volume, respiratory rate, minute ventilation and fraction of expiratory time to peak tidal expiratory flow to total expiratory time 36 weeks PMA, 3 months and 2 years CA
Secondary Cardiovascular Health assessed by echocardiography Echocardiography will be used to follow the transition from fetal to completed neonatal circulation, to measure superior vena cava flow, and to study mycardial function by the use of conventional two-dimensional echocardiography and tissue Doppler imaging. First week of life, 2nd week of life, at 36 weeks PMA and 2 years CA
Secondary Blood pressure Measurements of systolic, diastolic and mean pressure First week of life and at 36 weeks PMA and 2 years CA
Secondary Fatty acid (FA) profiles in blood Repeated dried blood spots (DBS) samples with approximately 10 µL blood will be collected for FA analyses. These analyses are important for assessing efficacy and protocol compliance. We will also collect 10 µL of fullblood for assessment of total lipid profile (Lipidomics). From birth until 36 weeks PMA
Secondary Markers of inflammation Inflammation panels will be used to assess markers of inflammation in fullblood and sputum From birth until 36 weeks PMA
Secondary Markers of metabolic status Metabolic pathway analyses (http://omictools.com/metabolic-pathways-category) will be performed to analyse and describe the metabolic conditions of the infants during hospitalization. Metabolites outside the standard clinical chemistry parameters will also be investigated ("untargeted metabolomics). Metabolomics will be performed by the use of dried blood spot samples From birth until 36 weeks PMA
Secondary Markers of nutritional status in blood The concentrations of electrolytes, minerals, albumin, alkaline phosphatase, vitamin A and D will be assessed regularly during hospitalization From birth until 36 weeks PMA
Secondary Micronutrient content in urine Spot urine will be obtained regularly to study the changes in electrolyte- and mineral homeostasis during the first week of life as well as during the phase of steady growth From birth until 36 weeks PMA
Secondary Evaluation of nutrient composition of expressed breast milk Repeated samples of breast milk will be collected for FA analyses, macronutrient content and vitamin A From birth until 36 weeks PMA
Secondary Gut microbiota Repeated samples of feces will be used to study the early fecal microbiota From birth until 36 weeks PMA
Secondary Inflammatory markers in sputum We will analyze the Expression of a standardized panel of inflammatory markers in collected laryngeal or tracheal secretion From birth until 36 weeks PMA
See also
  Status Clinical Trial Phase
Completed NCT01323283 - Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children N/A
Not yet recruiting NCT06274788 - Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment Phase 4
Withdrawn NCT04807478 - Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)